349-94-0Relevant articles and documents
Application of Vinamidinium Salt Chemistry for a Palladium Free Synthesis of Anti-Malarial MMV048: A bottom-Up Approach
Paymode, Dinesh J.,Chang, Le,Chen, Dan,Wang, Binglin,Kashinath, Komirishetty,Gopalsamuthiram, Vijayagopal,McQuade, D. Tyler,Vasudevan,Ahmad, Saeed,Snead, David R.
supporting information, p. 5400 - 5404 (2021/07/26)
MMV390048 (1) is a clinical compound under investigation for antimalarial activity. A new synthetic route was developed which couples two aromatic fragments while forming the central pyridine ring over two steps. This sequence takes advantage of raw materials used in the existing etoricoxib supply chain and eliminates the need for palladium catalysts, which were projected to be major cost-drivers.
METHODS FOR PREPARING 3-SUBSTITUTED-6-TRIFLUOROMETHYL PYRIDINES AND METHODS FOR USING 6-TRICHLOROMETHYL HALOGENATED PYRIDINES
-
Paragraph 0094; 0095, (2013/10/08)
3-substituted-6-trifluoromethyl pyridines are useful synthetic intermediates in the preparation of the N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines, which are useful in forming potent insecticides. Methods of forming such 3-substituted-6-trifluoromethyl pyridines are disclosed. Also disclosed are methods of using 6-trichloromethyl halogenated pyridines to form 3-substituted-6-trifluoromethyl pyridines are disclosed.
CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
-
, (2012/01/03)
The present invention comprises compounds of Formula (I). wherein: R1, R2, X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
Logistic flexibility in the preparation of isomeric halopyridinecarboxylic acids
Cottet, Fabrice,Schlosser, Manfred
, p. 11869 - 11874 (2007/10/03)
Although there are many conceivable ways to funtionalize, and specifically carboxylate, 2-chloro-4-(trifluoromethyl)pyridine optionally at all three vacant positions, it is more straightforward to prepare only the 2-chloro-4- (trifluoromethyl)pyridine-3-carboxylic acid (1) from this precursor and the other 6-chloro-4-(trifluoromethyl)pyridine-2- and -3-carboxylic acids (2 and 3) from a different one, viz. 5-bromo-2-chloro-4-(trifluoromethyl)pyridine. In the same manner, it proved more convenient to convert 5-chloro-2-(trifluoromethyl) pyridine in only two of the corresponding acids (6 and 7) and to make the third one (8) from 3-bromo-5-chloro-2-(trifluoromethyl)pyridine as an alternative starting material. All model substrates for functionalization were readily accessible from the correspondingly substituted chloroiodopyridine through heavy halogen displacement by in situ generated (trifluoromethyl)copper. Graphical Abstract